Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Osmotica Pharmaceuticals Plc (OSMT)  
$0.00 0.00 (9,900.00%) as of 4:30 Thu 5/2


Download
   
Exchange: N/A
Security Type: Common
Shares Out: 63,780,000
Market Cap: 6.38(K)
Last Volume: 0 Avg Vol: 0
52 Week Range: $0.000001 - $0.94
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:
   

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   RVL Pharmaceuticals is a holding company. Through its subsidiaries, Co. is a pharmaceutical company focused on the commercialization and development of products that target markets with underserved patients in the ocular medicine and medical aesthetics therapeutic areas. Co.'s portfolio includes RVL-1201, or Upneeq, (oxymetazoline hydrochloride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis, or droopy or low-lying eyelids in adults. Co. has expanded its commercialization activities among ophthalmology, optometry and oculoplastic specialties. Co. makes Upneeq available through RVL Pharmacy, Inc., its wholly-owned pharmacy.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 25,000,000
Total Buy Value $0 $0 $0 $38,750,000
Total People Bought 0 0 0 5
Total Buy Transactions 0 0 0 5
Total Shares Sold 0 0 35,088,392 35,088,392
Total Sell Value $0 $0 $1,602,356 $1,602,356
Total People Sold 0 0 2 2
Total Sell Transactions 0 0 6 6
End Date 2024-02-01 2023-10-31 2023-05-02 2022-05-02

   
Records found: 76
  Page 2 of 4  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Venkataraman Sriram Director   –       •       •   2022-08-08 4 B $1.55 $12,400,000 I/I 8,000,000 23,730,864 2.25 -28%     
   Devries Tina Marie EVP, Research & Development   •       –      –    2022-05-18 4 D $1.40 $7,626 D/D (5,447) 136,141     -
   Klein Christopher General Counsel & Secretary   •       –      –    2022-05-18 4 D $1.40 $8,578 D/D (6,127) 195,628     -
   Schaub James EVP and COO   •       –      –    2022-05-18 4 D $1.40 $8,782 D/D (6,273) 390,020     -
   Schaub James EVP and COO   •       –      –    2022-01-24 4 D $1.13 $10,856 D/D (9,607) 396,293     -
   Einhorn Andrew J. Chief Financial Officer   •       –      –    2022-01-24 4 D $1.13 $10,856 D/D (9,607) 141,473     -
   Klein Christopher General Counsel & Secretary   •       –      –    2022-01-24 4 D $1.13 $10,856 D/D (9,607) 201,755     -
   Devries Tina Marie EVP, Research & Development   •       –      –    2022-01-24 4 D $1.13 $10,856 D/D (9,607) 141,588     -
   Schaub James EVP and COO   •       –      –    2021-12-16 4 B $1.07 $100,366 D/D 93,800 405,900 2.74 32%     
   Cowan Gregory L Director   –       •      –    2021-08-27 4 D $3.31 $18,225 D/D (5,506) 50,055     -
   Weiss Fred G Director   –       •      –    2021-08-27 4 D $3.31 $18,225 D/D (5,506) 118,466     -
   Weiss Fred G Director   –       •      –    2021-07-02 4 A $0.00 $0 D/D 61,188 123,972     -
   Weiss Fred G Director   –       •      –    2021-06-18 4 D $2.89 $53,708 D/D (18,584) 62,784     -
   Cowan Gregory L Director   –       •      –    2021-06-18 4 D $2.89 $53,708 D/D (18,584) 55,561     -
   Einhorn Andrew J. Chief Financial Officer   •       –      –    2021-05-18 4 D $3.12 $20,177 D/D (6,467) 151,080     -
   Klein Christopher General Counsel & Secretary   •       –      –    2021-05-18 4 D $3.12 $20,177 D/D (6,467) 211,362     -
   Schaub James EVP and COO   •       –      –    2021-05-18 4 D $3.12 $20,658 D/D (6,621) 312,100     -
   Devries Tina Marie EVP, Research & Development   •       –      –    2021-05-18 4 D $3.12 $20,177 D/D (6,467) 151,195     -
   Devries Tina Marie EVP, Research & Development   •       –      –    2021-01-24 4 D $4.46 $42,803 D/D (9,597) 157,662     -
   Klein Christopher General Counsel & Secretary   •       –      –    2021-01-24 4 D $4.46 $42,838 D/D (9,605) 217,829     -
   Cowan Gregory L Director   –       •      –    2021-01-24 4 D $4.46 $24,552 D/D (5,505) 74,145     -
   Schaub James EVP and COO   •       –      –    2021-01-24 4 D $4.46 $43,204 D/D (9,687) 318,721     -
   Weiss Fred G Director   –       •      –    2021-01-24 4 D $4.46 $24,552 D/D (5,505) 81,368     -
   Einhorn Andrew J. Chief Financial Officer   •       –      –    2021-01-24 4 D $4.46 $43,119 D/D (9,668) 157,547     -
   Burgstahler David F Director   –       •       •   2020-11-20 4 D $0.00 $0 I/I (4,936,926) 0     -
  76 Records found
  1  2  3  4   
  Page 2 of 4
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us